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Background: Prostacyclin Synthase (PGIS) and Thromboxane syn-
thase (TXS) metabolize the cyclooxygenase product, prostaglandin H 
(2), into prostacyclin (PGI
2
) and thromboxane (TXA
2
) respectively. 
PGI
2
 and TXA
2
 have opposing actions, and changes in their ratio 
underlie many pathological conditions. PGIS over-expression inhibits 
cancer growth in a mouse model, while over-expression of TXS has 
the opposite effects. TXS expression has been reported in a number of 
cancers and is associated with poor prognosis and increased metastasis. 
The aim of this study was to examine expression patterns of PGIS and 
TXS in NSCLC relative to normal, to examine the effects of targeted 
TXS inhibition, and the mechanisms regulating these effects. 
Methods: A panel of retrospective resected human lung tumours 
(adenocarcinoma and squamous cell carcinoma) and matched normal 
samples were stained for PGIS and TXS by IHC. A 180-core tissue 
micro-array (TMA) was stained for TXS. TXS staining intensity was 
correlated with tumour grade. Immunoblotting for was carried out for 
PGIS and TXS using human tumour/normal matched protein samples. 
Cell proliferation/survival was examined by BrdU assay in A-549 (ad-
enocarcinoma) and SKMES-1 (squamous cell carcinoma) cell lines fol-
lowing 24-hour selective TXS inhibition with Ozagrel (500nM) alone, 
and in combination with a range of conventional chemotherapy drugs. 
Apoptosis was assessed following TXS inhibition by DNA laddering, 
Cell Death ELISA, and High Content Screening (HCS). RT2 Proﬁler 
PCR Arrays were used to analyse the expression of a panel of genes 
involved in tumourigenesis following selective TXS inhibition, relative 
to untreated controls. Stable cell lines over-expressing PGIS under the 
control of a CMV promoter were generated.
Results: PGIS was expressed in endothelial cells of normal lung, but 
absent in tumour sections, whereas TXS was over-expressed in lung 
cancer tissue. TXS expression was most abundant in low grade tumours 
(grade 1). Western Analysis revealed PGIS to be down-regulated or 
absent in human tumour protein samples, relative to normal, while 
TXS expression was up-regulated in tumours. Selective TXS inhibi-
tion signiﬁcantly reduced tumour cell proliferation/survival in both cell 
lines (p<0.05). Selective TXS inhibition in combination with a number 
of conventional chemotherapy drugs was investigated, with treatment 
in combination with Doxorubicin (10nM) showing the greatest efﬁcacy 
(p<0.001). Apoptosis was increased by TXS inhibition. Cellomics 
multi-parameter apoptosis signalling analysis by HCS showed enlarged 
nuclei, decreased f-actin staining and a loss in mitochondrial mass 
potential following TXS inhibition. TXS inhibition with Ozagrel (A-
549 cell line) resulted in down-regulation in the expression of a number 
of genes, including VEGF (3-fold), Integrin alpha 4 (8-fold), and 
CDC25A (5-fold). Tumour cells over-expressing PGIS proliferated at a 
signiﬁcantly slower rate than null transfected controls. 
Conclusions: Expression proﬁles of PGIS and TXS are altered in 
NSCLC, relative to normal. The balance in the proﬁle of these enzymes 
may underlie the pathogenesis of lung cancer. TXS is a survival factor 
in lung cancer, which is over-expressed in NSCLC. TXS inhibition, 
alone, or in combination with conventional chemotherapy, is a potential 
therapeutic target for the treatment of NSCLC. In contrast, strategies 
aimed at over-expressing PGIS may have potential for future chemo-
prevention strategies. 
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Background: AMG 706 is an investigational, highly selective, orally 
active inhibitor of angiogenesis with direct antitumor activity, selec-
tively targeting VEGF, PDGF and Kit receptors.
Methods: Phase 1b, open-label, dose-ﬁnding study (enrollment com-
pleted) of AMG 706 with C/P (Arm A), panitumumab (Arm B), or C/P 
and panitumumab (Arm C) in NSCLC patients. Objectives are to estab-
lish safety, PK, maximum tolerated dose, and objective response (per 
RECIST) of AMG 706. Patients ≥ 18 years with conﬁrmed unresect-
able stage IIIB or IV NSCLC, ECOG 0-1, no prior (Arms A, C) or ≤ 1 
prior (Arm B) chemotherapy regimen for NSCLC, and no prior VEGFr 
inhibitor or anti-EGFr antibody therapy, received escalating doses of 
AMG 706 (50mg, 125mg QD, 75mg BID) given continuously from 
day 3 of cycle 1 plus (Arm A) carboplatin (dose to produce an AUC of 
6.0mg/mL/min) and paclitaxel (200mg/m2) on day 1 of cycles 1-6 or 
(Arm B) panitumumab (9mg/kg IV day 1 of each cycle); or (Arm C) 
AMG 706 125mg QD (continuously from day 3 of cycle 1) plus C/P 
and panitumumab at the indicated doses (all cycles 21 days). Assess-
ments included dose-limiting toxicities (DLT) and tumor response 
(every 9 weeks from week 9).
Results: 45 pts were enrolled and received ≥ 1 dose of AMG 706 
(Arms A/B/C, n=23/16/6); 82% were disease stage IV; 88% in Arm 
B had prior chemotherapy. There were 3 DLTs: Arm A n=2, grade-2 
deep vein thrombosis (125mg QD) and grade-4 pulmonary embolism 
(50mg QD); Arm C n=1, grade-3 deep vein thrombosis (125mg QD). 
Treatment-related adverse events (AE) occurring in ≥ 10% of patients 
included: any AE, Arms A/B/C 91/94/100% of patients (grade 3, 
57/50/33%; grade 4, 17/0/33%; no grade 5); fatigue 57/69/67% (grade 
3, 26/19/17%; no grade 4/5), diarrhea 52/44/83% (grade 3, 4/6/0%; no 
grade 4/5), hypertension 35/38/0% (grade 3, 26/25/0%; no grade 4/5), 
pulmonary embolism 17/0/33% (all grade 4). 3 cases of cholecystitis 
occurred: all 75mg BID schedule, which was subsequently discontin-
ued. At 125mg QD, preliminary data showed that median AMG 706 PK 
parameters were not markedly changed with C/P coadministration. Best 
overall tumor response per RECIST is shown in the table.
Conclusions: In this study of patients with NSCLC, AMG 706 treat-
ment was tolerable when combined with C/P and/or panitumumab, with 
little effect on AMG 706 PK at 125mg QD. This dose will be further 
explored in future studies.
Patient tumor response data per RECIST
Arm A, n=23 Arm B, n=16 Arm C, n=6
Partial response, n (%) 4 (17) 0 (0) 1 (17)
Stable disease, n (%) 14 (61) 10 (63) 2 (33)
Progressive disease, n (%) 5 (22) 6 (37) 3 (50)
